column (e.g. in newspaper)
2024.04.03
What Are GLP-1 Receptor Agonists? A Cosmetic Physician Explains the Cutting Edge of Diabetes, Cardiovascular, and Neurological Research
To maximize your beauty, care for both the inside and outside is essential. We aim to bring advanced anti-aging treatments, such as peptide therapy common overseas, to our Japanese patients. While aesthetic medical approaches may offer more gradual results, they are crucial for building the foundation that supports beauty and youth. We combine nutritional therapy and lifestyle improvements with hormone replacement, peptide therapy, and regenerative medicine to propose personalized treatment plans. We provide long-term support for health and beauty from within.
Hello.
I am Yoko Maeda, Director of Aesthetic Medicine at BIANCA CLINIC.
This time, we focus on a topic that has garnered significant attention in the medical community in recent years.GLP-1 receptor agonistWe provide easy-to-understand explanations of the latest research and clinical trial trends.
※This article is for informational purposes only and does not guarantee therapeutic effects.
What are GLP-1 receptor agonists?
GLP-1 (glucagon-like peptide-1) is a type of hormone secreted from the intestine that plays a role in controlling blood sugar levels after meals.
This drug utilizes the function of GLP-1 and applies it as a medication.GLP-1 receptor agonistis.
Originally developed for the treatment of diabetes, it not only regulates blood sugar levels but alsoHormones involved in appetite, digestion, and overall metabolismResearch is being conducted as such.
Research on Diabetes Risk and GLP-1 Receptor Agonists
GLP-1 receptor agonists have been reported to potentially be associated not only with improved blood glucose control but also with the risk of developing diabetes.
Representative "SCALE StudyIn the study, obese subjects were divided into a GLP-1 group and a placebo group for comparison, and the results showed thatThe GLP-1 group had fewer new cases of diabetes.This trend has been reported.
However, these results are based on conditions of use as a therapeutic agent and do not guarantee the same effect for everyone.
Clinical Research in Cardiovascular and Neurological Diseases
GLP-1 receptor agonists extend beyond blood glucose control,cardiovascularやneurological disorderResearch is also advancing in this field.
「SELECT ExamReports indicate that the incidence of major cardiovascular events was reduced in the group using GLP-1 agents.
Furthermore, animal studies suggest neuroprotective effects,Clinical trials for neurodegenerative diseases such as Alzheimer's diseaseIt is also in progress.
It is believed that future research will further clarify the possibility that GLP-1 acts on the nervous system via blood glucose and metabolism.
New GLP-1 Receptor Agonists and Domestic Development Trends
Currently, GLP-1 is being combined with other drugs.Combination drugDevelopment is also underway.
Clinical studies have observed improvements in metabolism and changes in body weight, but safety and long-term data verification remain challenges for the future.
Additionally, Chugai Pharmaceutical in Japan is developingNew Oral GLP-1 Receptor AgonistA design with fewer restrictions on food and fluid intake is under consideration.
(※This information is at the development stage; commercialization and indications are undetermined.)
Summary: The Future of GLP-1 Receptor Agonists
GLP-1 receptor agonists, including glucose metabolism,
-
Impact on Cardiovascular Risk
-
Research on neurodegenerative diseases
-
Development of a New Oral Combination Type
Research is advancing across a wide range of fields.
We can expect the potential of GLP-1 receptor agonists to expand even further.
